Sanofi kicks off PhII test for RIPK1 in­hibitor, trig­ger­ing De­nali mile­stone; Ital­ian biotech flops key end­point in mus­cu­lar dy­s­tro­phy study

Close to 3 years af­ter Sanofi’s John Reed an­ted up $125 mil­lion in cash to bet on De­nali’s RIPK1 in­hibitor pro­gram, the phar­ma gi­ant has launched a Phase II as­sault on cu­ta­neous lu­pus ery­the­mato­sus.

Sanofi re­searchers say they have be­gun treat­ing pa­tients in the tri­al, trig­ger­ing a $15 mil­lion mile­stone for the new jour­ney planned for DNL758.

In choos­ing De­nali’s RIPK1 work, Sanofi was grab­bing hold of a drug that could cross the blood brain bar­ri­er in an at­tempt to reg­u­late in­flam­ma­tion and cell death.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER